ITGB3 and acute coronary syndrome: O’Connor et al. showed that there was higher incidence of major coronary events among patients with acute coronary syndrome with GPIIIa PlA2 mutation who were treated with orbofiban, an oral GPIIbIIIa antagonist, thus signaling that there might be an association between this mutation and coronary thrombosis.25